Phase I Study to Assess Irritation, Sensitization and Adhesion of a Novel Ibuprofen 200 mg TEPI Medicated Plaster

NCT ID: NCT03639571

Last Updated: 2019-04-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 33 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-08-09
• Study Completion Date: 2018-10-25

Brief Summary

This trial will be conducted with the aim to investigate the dermal response (skin irritation, sensitization) and the adhesion of Ibuprofen 200 mg TEPI Medicated Plaster as compared to a Placebo TEPI Plaster in two phases:

Induction Phase: multiple dose application of one active and one placebo plaster on 5 consecutive days in which the plasters remain in place for 23 hours ± 30 min a day and Challenge Phase: single dose application of one active and one placebo plaster which remain in place for 48 hours ± 30 min.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Test

Ibuprofen 200mg TEPI medicated plaster

Group Type: EXPERIMENTAL

Ibuprofen 200 mg TEPI Medicated Plaster

Intervention Type: DRUG

Ibuprofen 200 mg TEPI Medicated Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK

Placebo

Placebo TEPI Plaster

Group Type: PLACEBO_COMPARATOR

Placebo TEPI Plaster

Intervention Type: OTHER

Placebo TEPI Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK

Interventions

Ibuprofen 200 mg TEPI Medicated Plaster

Ibuprofen 200 mg TEPI Medicated Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK

Intervention Type: DRUG

Placebo TEPI Plaster

Placebo TEPI Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Male and female subject
• Age between 18 and 65 years
• Physically and mentally healthy as judged by means of medical and standard laboratory examinations
• Non-smokers or ex-smokers (stopped at least 6 months ago) with a smoking history of ≤5 pack-year equivalents (1 pack-year equivalent is equal to smoking 1 pack per day for 1 year*****) and non-users of other nicotine containing products, confirmed by urine cotinine test
• Weight ≥ 60 kg and BMI within the range (including the borders) of 18.0 to 30.0 kg/m2
• Informed consent given in written form.

Exclusion Criteria

• Participation in another clinical trial at same time or within the preceding 90 days (calculated from the date of the final examination of the previous study)
• Fertile women without reliable contraception method. List of allowed medically accepted contraceptive methods and the allowed HRT (used at least 4 weeks prior entry visit and not to be changed for the duration of the study):
• combination of 2 barrier methods: female/male condoms, diaphragms, spermicides
• intrauterine devices (IUD): inert or copper-releasing or progestinreleasing IUD
• hormonal methods: combined oestrogen/progestin injectable contraceptives, progestin only injectable contraceptives, Norplant implants, skin patches, NuvaRing®
• Hormone Replacement Therapy (HRT)
• voluntary sterilization (female tubal occlusion).
• Randomisation into the present trial more than once
• History of drug abuse or use of illegal drugs: use of soft drugs, e.g. marihuana within 6 months of screening or hard drugs, e.g. cocaine, amphetamines, phencyclidine within 1 year of screening
• Alcohol abuse, i.e. regular use of more than 2 units of alcohol per day or 10 units per week or a history of alcoholism (one unit of alcohol equals 250 ml beer, 125 ml wine or 25 ml spirits) or recovered alcoholics
• Positive drug screening and/or positive alcohol test at entry (screening) visit, or on Day -1, or on Day 19
• Pregnant and/or nursing women. Positive pregnancy test at entry (screening) visit, or on Day -1, or on Day 19
• Allergic diathesis or any clinically significant allergic disease (i.e. asthma or bronchial hyper-reactivity, contact dermatitis)
• Known allergy to sticking plaster or to the ingredients of the products
• Dermatologic disease that might interfere with the evaluation of test site reaction
• Active skin disease
• Subjects with tattoos, sunburn, coloration, open sores or scars on site of application
• Subject with excessive hair at site of plaster application
• Intake of systemic drugs interfering with the immune system (e.g. antiinflammatories, corticosteroids, immune-suppressants or antihistamines) within 2 weeks before and during the study
• Topical therapy with analgesics or corticosteroids or antihistamines at the application sites within 2 weeks before and during the study
• Intake or administration of any systemic or topical medication (including prescribed medication, OTC medication, and especially use of ointments, gels or patches for skin application) within 2 weeks before entry (screening) visit and during the study
• Use of topical products without medication at the application sites (including make-up, sunscreen, creams, lotions, powders, alcohol) from 7 days prior entry (screening) visit and during the study
• Intensive UV-light exposure (sunbath) at the application sites within 2 weeks before entry (screening) visit and during the study
• Use of tanning beds at the application sites within 2 weeks before entry (screening) visit and during the study
• Any method of hair removal (e.g. waxing, shaving, epilating, laser) at the application sites from 7 days before entry (screening) visit and during the study
• Presence or a history of clinically significant cardiovascular, renal, hepatic, pulmonary, metabolic, endocrine, haematological, gastrointestinal, neurological, psychiatric or other diseases (e.g. autoimmune disorders such as lupus erythematosus)
• Clinically significant illness within 4 weeks before entry (screening) visit and during the study
• Positive serologic findings for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies [
• Systolic blood pressure outside the range of 100 to 140 mmHg and/or diastolic blood pressure outside the range of 60 to 90 mmHg12 at entry (screening) visit
• Heart rate outside the range of 50 to 90 beats/min at entry (screening) visit
• Respiratory rate outside the range of 12-24 breaths/min at entry (screening) visit
• Axillary body temperature outside the interval of 35.5 to 37.1°C at entry (screening) visit
• Any clinically significant abnormality of the resting ECG (12-lead) (i.e. AV block, 2° to 3°, sinus bradycardia, sick sinus syndrome, SA block)
• Laboratory values outside normal range with clinical relevance at entry (screening) examination
• Not fulfilling study specific restrictions and diet
• Subjects who are known or suspected:
• not to comply with the study directives
• not to be reliable or trustworthy
• not to be capable of understanding and evaluating the information given to them as part of the formal information policy (informed consent), in particular regarding the risks and discomfort to which they would agree to be exposed
• to be in such a precarious financial situation that they no longer weigh up the possible risks of their participation and the inconvenience they may be involved in
• subject is a dependent person, e.g. a relative, family member, or member of the investigator's or sponsor's staff
• subject is in custody or submitted to an institution due to a judicial order.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Cooperative Clinical Drug Research and Development AG (CCDRD AG)

OTHER

Sponsor Role: collaborator

Medherant Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

MHAT

Sofia, , Bulgaria

Countries

Bulgaria

Other Identifiers

MED-IBU-102

Identifier Type: -

Identifier Source: org_study_id